U01.11.073 Arachidonic acid pathways

Learning Objectives

Differentiate between the Cyclooxygenase (COX) and Lipoxygenase (LOX) branches of the arachidonic acid cascade. Master the specific physiological effects of Prostacyclins, Prostaglandins, Thromboxane, and Leukotrienes, and identify the exact molecular targets of common anti-inflammatory pharmacological agents.


1. The Upstream Cascade: Membrane to Acid

The pathway begins at the cell membrane, where phospholipids are converted into Arachidonic Acid. This is the primary site of action for potent systemic anti-inflammatories.

Enzyme / Step Inhibitor Clinical Effect
Phospholipase A2 Glucocorticoids Inhibits both LOX and COX pathways; blocks NF-κB.
Arachidonic Acid N/A The precursor for all eicosanoids.


2. The Cyclooxygenase (COX) Branch

COX enzymes convert arachidonic acid into cyclic endoperoxides, leading to the production of prostanoids and thromboxane. These regulate vascular tone, platelet activity, and uterine contractions.

Product Primary Physiological Effects Pharmacological Analog
Prostacyclin (PGI2) ↓ Platelet aggregation; ↓ Vascular tone (vasodilation). Epoprostenol
Prostaglandin (PGE1/2) ↑ Uterine tone; PGE2 maintains the ductus arteriosus. Alprostadil, Dinoprostone
Prostaglandin (PGF2α) ↑ Uterine tone; ↑ Bronchial tone. Carboprost
Thromboxane (TXA2) ↑ Platelet aggregation; ↑ Vascular tone (vasoconstriction). N/A (Inhibited by Aspirin)

3. The Lipoxygenase (LOX) Branch

The LOX pathway produces leukotrienes, which are primarily involved in asthma, allergic reactions, and inflammatory cell recruitment.

Product / Target Mechanism / Inhibitor Clinical Use
5-Lipoxygenase Zileuton Blocks the synthesis of all leukotrienes.
LTB4 ↑ Neutrophil chemotaxis. Inflammatory recruitment.
LTC4, LTD4, LTE4 Montelukast / Zafirlukast Blocks LT receptors; used in asthma management.

Activity:


High-Yield Mnemonics & Tips:

  • PGI2 (Prostacyclin): Platelet-Gathering Inhibitor. It keeps blood flowing.
  • LTB4: Neutrophils arrive “B4” (before) others. It is the primary recruiter.
  • Aspirin: Irreversibly inhibits COX-1 and COX-2. Most other NSAIDs (Ibuprofen, Naproxen) are reversible.
  • Celecoxib: A selective COX-2 inhibitor; spares the gastric mucosa (COX-1) but may increase cardiovascular risk.

Activity: